Level of Depression, Criminogenic Cognition, Relapse Risk, and Quality of Life among Patients with Substance Use Disorders : Level of Depression, Criminogenic Cognition and QoL

Mafia Shahzadi; Khalid Mahmood

doi:10.54393/pjhs.v4i09.1030

Authors

Mafia Shahzadi Department of Applied Psychology, Government College University Faisalabad, Faisalabad, Pakistan
Khalid Mahmood Department of Applied Psychology, Government College University Faisalabad, Faisalabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v4i09.1030

Keywords:

Opioid Use Disorders, Depression, Quality of Life, Relapse Risk

Abstract

Substance use disorders (SUDs) involve symptoms caused by using a substance that an individual continues taking despite its negative effects. Patients with opioid use disorder (OUD) and other substance use disorders (O-SUDs) experience psychosocial problems that affect their quality of life (QOL). Objective: To determine the difference in depression, criminogenic cognition, relapse risk, and quality of life between patients with OUD and O-SUDs. Methods: In this cross-sectional study, the sample was collected from different rehabilitation centres in Faisalabad and Lahore. A purposive sampling technique was used to collect data from individuals with OUD (150) and O-SUDs (150) with relapse conditions through Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST), Criminogenic Cognition Scale (CCS), Patient Health Questionnaire-9 (PHQ-9), Relapse Risk Scale (RRS) and WHO Quality of Life (WQOL). The collected data were prepared for statistical analysis using SPSS, Version-26. Results: The finding shows a significant difference between patients with OUD and with O-SUDs on the variables of PHQ-9, short-term orientation, negative attitudes toward authority, notions of entitlement, failure to accept responsibility, insensitivity to the impact of crime, and criminogenic cognition. In addition, a significant difference was found between patients with OUD and with O-SUDs on anxiety problems, positive expectancies and compulsivity, abstinence violation effect, low self-efficacy, relapse risk and QOL. Conclusions: It is concluded that depressive symptoms, criminogenic cognition, relapse risk conditions, and quality of life were higher among patients with OUD than patients with O-SUDs.

References

Poudel A and Gautam S. Age of onset of substance use and psychosocial problems among individuals with substance use disorders. BMC Psychiatry. 2017 Jan; 17: 10. doi: 10.1186/s12888-016-1191-0. DOI: https://doi.org/10.1186/s12888-016-1191-0

Morin KA, Eibl JK, Gauthier G, Rush B, Mushquash C, Lightfoot NE, et al. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data. Harm Reduction Journal. 2020 Jul; 17(1): 51. doi: 10.1186/s12954-020-00396-x. DOI: https://doi.org/10.1186/s12954-020-00396-x

Lutz PE and Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends in Neuroscience. 2013 Mar; 36(3): 195–206. doi: 10.1016/j.tins.2012.11.002. DOI: https://doi.org/10.1016/j.tins.2012.11.002

Williams JT, Ingram SL, Henderson G, Chavkin C, Zastrow M von, Schulz S, et al. Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Dolphin AC, editor. Pharmacology Reviews. 2013 Jan; 65(1): 223–54. doi: 10.1124/pr.112.005942. DOI: https://doi.org/10.1124/pr.112.005942

Datta D, Mishra S, Rajest SS. Quantification of tolerance limits of engineering system using uncertainty modeling for sustainable energy. International Journal of Intelligent Network. 2020 Jan; 1: 1–8. doi: 10.1016/j.ijin.2020.05.006. DOI: https://doi.org/10.1016/j.ijin.2020.05.006

Ghabrash MF, Bahremand A, Veilleux M, Blais-Normandin G, Chicoine G, Sutra-Cole C, et al. Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. Journal of Dual Diagnosis. 2020 Apr; 16(2): 191–207. doi: 10.1080/15504263.2020.1726549. DOI: https://doi.org/10.1080/15504263.2020.1726549

Strang J, Volkow ND, Degenhardt L, Hickman M, Johnson K, Koob GF, et al. Opioid use disorder. Nature Reviews Disease Primer. 2020 Jan; 6(1): 1–28. doi: 10.1038/s41572-019-0137-5. DOI: https://doi.org/10.1038/s41572-019-0137-5

Blanco C and Volkow ND. Management of opioid use disorder in the USA: present status and future directions. The Lancet. 2019 Apr; 393(10182): 1760–72. doi: 10.1016/S0140-6736(18)33078-2. DOI: https://doi.org/10.1016/S0140-6736(18)33078-2

Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: Results from electronic health records data. Journal of Substance Abuse Treatment. 2017 Jun; 77: 26–30. doi: 10.1016/j.jsat.2017.03.006. DOI: https://doi.org/10.1016/j.jsat.2017.03.006

Halbert B, Davis R, Wee CC. Disproportionate longer-term opioid use among US adults with mood disorders. Pain. 2016 Nov; 157(11): 2452–7. doi: 10.1097/j.pain.0000000000000650. DOI: https://doi.org/10.1097/j.pain.0000000000000650

Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behaviour. 2009 Jun; 34(6): 498–504. doi: 10.1016/j.addbeh.2009.01.002. DOI: https://doi.org/10.1016/j.addbeh.2009.01.002

Barry DT, Beitel M, Cutter CJ, Fiellin DA, Madden LM, Lipkind N, et al. Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder. Drug Alcohol Depend. 2021 Apr; 221: 108608. doi: 10.1016/j.drugalcdep.2021.108608. DOI: https://doi.org/10.1016/j.drugalcdep.2021.108608

McHugh RK, Votaw VR, Barlow DH, Fitzmaurice GM, Greenfield SF, Weiss RD. Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods. Contemporary of Clinical Trials. 2017 Sep; 60: 105–12. doi: 10.1016/j.cct.2017.07.006. DOI: https://doi.org/10.1016/j.cct.2017.07.006

Grattan A, Sullivan MD, Saunders KW, Campbell CI, Korff MRV. Depression and Prescription Opioid Misuse Among Chronic Opioid Therapy Recipients with No History of Substance Abuse. Annals of Family Medicine. 2012 Jul; 10(4): 304–11. doi: 10.1370/afm.1371. DOI: https://doi.org/10.1370/afm.1371

Bogdanowicz KM, Stewart R, Broadbent M, Hatch SL, Hotopf M, Strang J, et al. Double trouble: Psychiatric comorbidity and opioid addiction—All-cause and cause-specific mortality. Drug Alcohol Depend. 2015 Mar; 148: 85–92. doi: 10.1016/j.drugalcdep.2014.12.025. DOI: https://doi.org/10.1016/j.drugalcdep.2014.12.025

Wooditch A, Tang LL, Taxman FS. Which Criminogenic Need Changes Are Most Important in Promoting Desistance from Crime and Substance Use? Criminal Justice Behaviour. 2014 Mar; 41(3): 276–99. doi: 10.1177/0093854813503543. DOI: https://doi.org/10.1177/0093854813503543

Topalli V. When Being Good is Bad: An Expansion of Neutralization Theory. In: Recent Developments in Criminological Theory. Routledge; 2009.

Theofilou P. Quality of Life: Definition and Measurement. European Journal of Psychology. 2013 Feb; 9(1): 150–62. doi: 10.5964/ejop.v9i1.337. DOI: https://doi.org/10.5964/ejop.v9i1.337

Humeniuk R, Henry-Edwards S, Ali R, Poznyak V, Monteiro MG, Organization WH. The Alcohol, Smoking and Substance involvement Screening Test (ASSIST): manual for use in primary care. World Health Organization; 2010 [Last cited: 12th May 2023]. Available of: https://apps.who.int/iris/handle/10665/44320.

Tangney JP, Stuewig J, Furukawa E, Kopelovich S, Meyer PJ, Cosby B. Reliability, Validity, and Predictive Utility of the 25-item Criminogenic Cognitions Scale (CCS). Criminal Justice Behaviour. 2012 Oct; 39(10): 1340–60. doi: 10.1370/afm.1139. DOI: https://doi.org/10.1177/0093854812451092

Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, et al. Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population. Annals of Family Medicine. 2010 Jul; 8(4): 348–53. doi: DOI: https://doi.org/10.1370/afm.1139

Hussain A and Malik H. Development and Validation of Relapse Risk Scale for Substance Dependents in Pakistan. 2016.

World Health Organization. The World Health Organization quality of life (WHOQOL) - BREF [Internet]. World Health Organization; 2004 [Last cited: 12th May 2023]. Report No.: WHO/HIS/HSI Rev.2012.02. Available at: https://apps.who.int/iris/handle/10665/77773.

Kelly JF, Saitz R, Wakeman S. Language, Substance Use Disorders, and Policy: The Need to Reach Consensus on an “Addiction-ary.” Alcohol Treatment Quarterly. 2016 Jan; 34(1): 116–23. doi: DOI: https://doi.org/10.1080/07347324.2016.1113103

Sahu K and Sahu S. Substance Abuse Causes and Consequences. Bangabasi Academic Journal. 2012 Dec; 9: 52–61.

Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment. 2006 Jun; 30(4): 355–62. doi: 10.1016/j.jsat.2006.03.012. DOI: https://doi.org/10.1016/j.jsat.2006.03.012

Namchuk AB, Lucki I, Browne CA. Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder. Advance in Drug and Alcohol Research. 2022; 2: 10254. doi: 10.3389/adar.2022.10254. DOI: https://doi.org/10.3389/adar.2022.10254

Guillem E, Pelissolo A, Vorspan F, Bouchez-Arbabzadeh S, Lépine JP. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting]. L’Encephale. 2009 Jun; 35(3): 226–33. doi: 10.1016/j.encep.2008.03.010. DOI: https://doi.org/10.1016/j.encep.2008.03.010

Barrett EL, Mills KL, Teesson M. Hurt people who hurt people: Violence amongst individuals with comorbid substance use disorder and post traumatic stress disorder. Addict Behav. 2011 Jul; 36(7): 721–8. doi: 10.1016/j.addbeh.2011.02.005. DOI: https://doi.org/10.1016/j.addbeh.2011.02.005

Kraanen FL, Scholing A, Emmelkamp PMG. Substance Use Disorders in Forensic Psychiatry: Differences Among Different Types of Offenders. International Journal of Offender Therapy Comparative Criminology. 2012 Dec; 56(8): 1201–19. doi: 10.1177/0306624X11420252. DOI: https://doi.org/10.1177/0306624X11420252

Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, et al. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. Journal of Substance Abuse Treatment. 2018 Feb; 85: 49–55. doi: 10.1016/j.jsat.2017.04.016. DOI: https://doi.org/10.1016/j.jsat.2017.04.016

Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018 Mar; 190(9): E247–57. doi: 10.1503/cmaj.170958. DOI: https://doi.org/10.1503/cmaj.170958

Roehrs T, Sibai M, Roth T. Sleep and alertness disturbance and substance use disorders: A bi-directional relation. Pharmacology and Biochemistry Behaviour. 2021 Apr; 203: 173153. doi: 10.1016/j.pbb.2021.173153. DOI: https://doi.org/10.1016/j.pbb.2021.173153

Burns MK and VanDerHeyden AM. Using Response to Intervention to Assess Learning Disabilities: Introduction to the Special Series. Assess Effect Interval. 2006 Oct; 32(1): 3–5. doi: 10.1177/15345084060320010201. DOI: https://doi.org/10.1177/15345084060320010201

Domino KB, Hornbein TF, Polissar NL, Renner G, Johnson J, Alberti S, et al. Risk Factors for Relapse in Health Care Professionals With Substance Use Disorders. JAMA. 2005 Mar; 293(12): 1453–60. doi: 10.1001/jama.293.12.1453. DOI: https://doi.org/10.1001/jama.293.12.1453

Mackiewicz M, Brown RE, Price ET, Sargent L. Quality of life in older adults with opioid use disorder: A scoping review. Geriatric Nurse (Lond). 2022 Jul; 46: 118–24. doi: 10.1016/j.gerinurse.2022.05.002. DOI: https://doi.org/10.1016/j.gerinurse.2022.05.002

Kwon M, Park E, Dickerson SS. Adolescent substance use and its association to sleep disturbances: A systematic review. Sleep Health. 2019 Aug; 5(4): 382–94. doi: 10.1016/j.sleh.2019.06.001. DOI: https://doi.org/10.1016/j.sleh.2019.06.001

Navarro-Martínez R, Chover-Sierra E, Colomer-Pérez N, Vlachou E, Andriuseviciene V, Cauli O. Sleep quality and its association with substance abuse among university students. Clinical Neurology and Neurosurgery. 2020 Jan; 188: 105591. doi: 10.1016/j.clineuro.2019.105591. DOI: https://doi.org/10.1016/j.clineuro.2019.105591

Rather YH, Bashir W, Sheikh AA, Amin M, Zahgeer YA. Socio-demographic and Clinical Profile of Substance Abusers Attending a Regional Drug De-addiction Centre in Chronic Conflict Area: Kashmir, India. Malaysian Journal of Medical Science MJMS. 2013 May; 20(3): 31–8. doi:

Nolte-Troha C, Roser P, Henkel D, Scherbaum N, Koller G, Franke AG. Unemployment and Substance Use: An Updated Review of Studies from North America and Europe. Healthcare. 2023 Jan; 11(8): 1182. doi: 10.3390/healthcare11081182. DOI: https://doi.org/10.3390/healthcare11081182

Kulesza M, Larimer ME, Rao D. Substance Use Related Stigma: What we Know and the Way Forward. Journal of Addiction Behaviour, Therapy and Rehabilitation. 2013 May; 2(2): 782. doi: 10.4172/2324-9005.1000106. DOI: https://doi.org/10.4172/2324-9005.1000106

Mahsoon AN, Almashat L, Alsubaui N, Hindi S, Alharbi S, Yaghmour S, et al. Socio-Demographics of Initial Substance Use Exposure and Its Relation to Progression: A Cross-Sectional Study in Saudi Arabia. Cureus. 2023 Aug; 15(8): e42795. doi: 10.7759/cureus.42795. DOI: https://doi.org/10.7759/cureus.42795

El-Tantawy A, Raya Y, Al-Yahya A, El-Desoky I. Amphetamine Abuse among Patients with First Episode of Acute Psychosis. Current Psychiatry Journal. 2010 Jan;17(1): 73-81.